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ORIGINAL INVESTIGATION
Sex, age, type of diabetes and incidence 
of atrial fibrillation in patients with diabetes 
mellitus: a nationwide analysis
Arnaud Bisson1, Alexandre Bodin1, Grégoire Fauchier2, Julien Herbert1,3, Denis Angoulvant1,4, 
Pierre Henri Ducluzeau2,5, Gregory Y. H. Lip6,7 and Laurent Fauchier1* 
Abstract 
Background: There remain uncertainties regarding diabetes mellitus and the incidence of atrial fibrillation (AF), in 
relation to type of diabetes, and the interactions with sex and age. We investigated whether diabetes confers higher 
relative rates of AF in women compared to men, and whether these sex-differences depend on type of diabetes and 
age.
Methods: All patients aged ≥ 18 seen in French hospitals in 2013 with at least 5 years of follow-up without a history 
of AF were identified and categorized by their diabetes status. We calculated overall and age-dependent incidence 
rates, hazard ratios, and women-to-men ratios for incidence of AF in patients with type 1 and type 2 diabetes (com-
pared to no diabetes).
Results: In 2,921,407 patients with no history of AF (55% women), 45,389 had prevalent type 1 diabetes and 345,499 
had prevalent type 2 diabetes. The incidence rates (IRs) of AF were higher in type 1 or type 2 diabetic patients than 
in non-diabetics, and increased with advancing age. Among individuals with diabetes, the absolute rate of AF was 
higher in men than in women. When comparing individuals with and without diabetes, women had a higher adjusted 
hazard ratio (HR) of AF than men: adjusted HR 1.32 (95% confidence interval 1.27–1.37) in women vs. 1.12(1.08–1.16) 
in men for type 1 diabetes, adjusted HR 1.17(1.16–1.19) in women vs. 1.10(1.09–1.12) in men for type 2 diabetes.
Conclusion: Although men have higher absolute rates for incidence of AF, the relative rates of incident AF associated 
with diabetes are higher in women than in men for both type 1 and type 2 diabetes.
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Introduction
Atrial fibrillation (AF) and diabetes mellitus are common 
worldwide and their incidence is increasing, representing 
a significant public health and economic burden as well 
as an increase in individual risk of morbidity and mortal-
ity. Both conditions are closely related, and AF patients 
with diabetes are at higher risk of cardiovascular events 
compared to non-AF patients. Patients with diabetes are 
at increased risk of incident AF but there remain uncer-
tainties regarding diabetes mellitus and the incidence of 
AF, in relation to type of diabetes, and the interactions 
with sex and age.
Patients with type II diabetes have a higher risk of 
prevalent AF (around 15%), and of incident AF (around 
0.8%/year), which is partly related to other associated 
risk factors frequently encountered in these patients 
[1, 2]. Until recently, type I diabetes was considered as 
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long-term hyperglycaemia in diabetes per se would not 
itself promote AF; instead, the risk of AF seemed linked 
to insulin resistance, which is also the mechanism by 
which hypertension and obesity might be associated with 
an increased risk of AF [3, 4]. Obesity and type 2 dia-
betes are risk factors for AF [5], possibly because both 
increase epicardial adipose tissue, which is the source of 
proinflammatory adipocytokines that can lead to fibro-
sis of the underlying myocardium [6]. Diabetes could be 
an independent risk factor for AF when one specifically 
considers those patients aged < 75 [7]. Also, cardiovascu-
lar diseases are the major component of the excess risk of 
clinical events in diabetes and the proportional increase 
is higher among women than among men [8–10]. Com-
pared with the general population, the risk of AF in men 
with type 1 diabetes is slightly raised, whereas for female 
patients it may be 50% higher [11]. An age and sex inter-
action with type of diabetes may thus influence sex-dif-
ferences in the diabetes-related risk of AF. Moreover, 
several of the above findings are related to relatively older 
studies not taking into account contemporary changes in 
diabetes definition and management strategy [12, 13].
We further investigate these issues and performed a 
nationwide longitudinal cohort study to examine whether 
diabetes confers higher relative rates of AF in women 
compared to men, and whether these sex-differences 
depend on type of diabetes and age.
Methods
Study design
This longitudinal cohort study was based on the national 
hospitalization database covering hospital care from the 
entire French population. The data for all patients admit-
ted in French hospitals in France from January to Decem-
ber 2013 with at least 5 years of complete follow-up (or 
dead earlier) were collected from the national adminis-
trative PMSI (Programme de Médicalisation des Systèmes 
d’Information) database, which was based on the US 
Medicare system. Through this program, medical activ-
ity is recorded in a database, computed, and rendered 
anonymous. It includes more than 98% of the French 
population (67 million people) from birth (or immigra-
tion) to death (or emigration), even if a person changes 
occupation or retires. This process allows the determina-
tion of each hospital’s budget, in 1546 French healthcare 
facilities for both public and private hospitals. Each hos-
pitalization is encoded in a standardized dataset, which 
includes information about the patient (age during first 
hospitalization in 2013 and sex), hospital, stay (date of 
admission, date of discharge, and modes of discharge), 
pathologies, and procedures. Routinely collected medical 
information includes the principal diagnosis and second-
ary diagnoses. In the PMSI system, identified diagnoses 
are coded according to the International Classification 
of Diseases, Tenth Revision (ICD-10). All medical pro-
cedures are recorded according to the national nomen-
clature, Classification Commune des Actes Medicaux 
(CCAM). The PMSI contains individual anonymized 
information on each hospitalization that are linked to 
create a longitudinal record of hospital stays and diag-
noses for each patient. The reliability of PMSI data has 
already been assessed and this database has previously 
been used to study patients with cardiovascular con-
ditions, including AF [14–16]. Use of medication was 
identified from a 1/97 permanent random sample of the 
complete French nationwide claims database (Echantil-
lon Généraliste de Bénéficiaires, EGB – general sample of 
healthcare beneficiaries), which is another database not 
linked to the PMSI database but has been previously used 
to study patients with diabetes in France [17]) We report 
information for patients with same inclusion criteria 
than those in the present analysis (patients seen in 2013 
with at least 5 years of follow-up). Patients were consid-
ered to be included in a treatment group if they received 
a treatment from that class of drugs for ≥ 60 days within 
6 months after enrolment.
The study was conducted retrospectively and, as 
patients were not involved in its conduct, there was no 
impact on their care. Ethical approval was not required, 
as all data were anonymized. The French Data Protec-
tion Authority granted access to the PMSI data. Proce-
dures for data collection and management were approved 
by the Commission Nationale de l’Informatique et des 
Libertés (CNIL), the independent National Ethical Com-
mittee protecting human rights in France, which ensures 
that all information is kept confidential and anonymous, 
in compliance with the Declaration of Helsinki (authori-
zation number 1897139).
Study population
From 1 January 2013 to 31 December 2013, 3,381,472 
adults (age ≥ 18 years) were hospitalized for any reason in 
French hospitals and then had at least 5 years of complete 
follow-up (or suffered in-hospital death earlier). Patient 
information (demographics, comorbidities, medical his-
tory, and events during hospitalization or follow-up) was 
described using data collected in the hospital records. 
For each hospital stay, combined diagnoses at discharge 
were obtained. Each diagnosis was identified using ICD-
10 codes and because the information was on the basis of 
these codes, there were no missing values. Diabetes was 
identified with the following ICD-10 codes: E10, O240 for 
type 1 diabetes; E11, O241-9 for type 2 diabetes. Patients 
had a period of 3 years (2010 to 2013) to determine medi-
cal history. Exclusion criteria were age < 18 years and his-
tory of AF.
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Outcomes
Patients were followed until 31 December 2019 for the 
occurrence of outcomes. We aimed to evaluate the inci-
dence of AF. This was evaluated with follow-up starting 
from the date of first hospitalization in 2013 until the date 
of AF or date of last news in the absence of the outcome. 
Information on AF during the follow-up was obtained by 
analysing the PMSI codes for each patient. We analysed 
the incidence of AF separately in patients with type 1 and 
type 2 diabetes, with non-diabetic patients as the refer-
ence group.
Statistical analysis
Qualitative variables are described as frequency and per-
centages and quantitative variable as means (standard 
deviations [SDs]). A multivariable analysis for clinical 
outcomes during the whole follow-up in the groups of 
interests was performed using a Cox model with relevant 
baseline characteristics among age, cardiovascular risk 
factors (smoking, obesity, hypertension, dyslipidemia, 
alcohol related diagnoses) and non-cardiovascular 
comorbidities and reporting hazard ratios. We report 
incidence rates (IR = events/1000 person-years) and haz-
ard ratios (HR) in women and in men, and then women-
to-men ratios (WMR = HR women/HR men) with 95% 
confidence intervals (CIs). We present unadjusted WMR 
(unadjusted HR in women/unadjusted HR in men) and 
adjusted WMR (adjusted HR in women/adjusted HR in 
men).
Owing to the non-randomized nature of the study and 
considering the significant differences in baseline charac-
teristics in women and men, propensity-score matching 
was also used to control for potential confounders. Pro-
pensity scores were calculated using logistic regression 
with female sex as the dependent variable. The propen-
sity score included the cardiovascular risk factors and 
non-cardiovascular comorbidities from baseline charac-
teristics listed in Table 1. For each female patient, a pro-
pensity score-matched male patient was selected (1:1) 
using the one-to-one nearest neighbour method (with 
a calliper of 0.0001 of the SD of the propensity score on 
the logit scale) and no replacement. We assessed the dis-
tributions of demographic data and comorbidities in the 
two cohorts with standardized differences, which were 
calculated as the difference in the means or proportions 
of a variable divided by a pooled estimate of the SD of 
that variable. A standardized difference of 5% or less indi-
cated a marginal difference between means of the two 
cohorts (Additional file 1: Fig. S1).
All comparisons with p < 0.05 were considered statis-
tically significant. All analyses were performed using 
Enterprise Guide 7.1, (SAS Institute Inc., SAS Campus 
Drive, Cary, North Carolina), USA and STATA version 
16.0 (Stata Corp, College Station, TX).
Results
We included 2,921,407 patients seen in French hospi-
tals in 2013 with no history of AF (55% women), among 
whom 45,389 had prevalent type 1 diabetes and 345,499 
had prevalent type 2 diabetes (Fig. 1). Characteristics of 
patients excluded because of AF are in Additional file 1: 
Table  S1. Population characteristics at baseline showed 
that men were older and had more prevalent comorbidi-
ties than women (Table 1). Individuals with diabetes had 
more prevalent comorbidities than those without diabe-
tes, and those with type 2 diabetes had more prevalent 
comorbidities than those with type 1 diabetes (Additional 
file  1: Table  S2). Using data on medications for a 1/97 
sample, those with diabetes were more frequently treated 
(approximately 2–threefold) with angiotensin-converting 
enzyme inhibitor or angiotensin receptor blocker, beta-
blockers, diuretics, antiarrhythmic agents, anti-throm-
botic therapy and statins than patients without diabetes 
(Additional file  1: Table  S3). Among diabetic patients, 
women were less treated with these medications than 
men except for diuretics and calcium channel blocker.
During 13.5 million person-years of follow-up, 327,012 
patients with new-onset AF were identified. The IRs of 
AF was higher in diabetic than in non-diabetic patients 
and increased with advancing age, for both type 1 or type 
2 diabetes (Fig. 2).
Among women, IR of AF was 1.68%/year in those with 
no diabetes, 2.63%/year in those with type 1 diabetes, and 
3.38%/year in those with type 2 diabetes. The IRs for AF 
were higher in men than in women (2.92%/year in men 
with no diabetes, 3.37%/year in men with type 1 diabetes, 
and 4.96%/year in men with type 2 diabetes) irrespective 
of diabetes status and age (Table 2, Top panels in Fig. 3 
and 4). The adjusted HR for women (diabetes:no dia-
betes) was therefore 1.32 (95% CI 1.27–1.37) for type 1 
diabetes and 1.17 (95% CI 1.16–1.19) for type 2 diabetes. 
The corresponding adjusted HRs for men were 1.12 (95% 
CI 1.08–1.16) for type 1 diabetes and 1.10 (95% CI 1.09–
1.12) for type 2 diabetes (Table 2). The adjusted HRs for 
women were significantly higher than the adjusted HRs 
for men as shown with the adjusted women-to-men 
ratios (adjusted WMR = adjusted HR women compared 
to adjusted HR men) = 1.18 (95% CI 1.12–1.24) for type 1 
diabetes and 1.10 (95% CI 1.08–1.12) for type 2 diabetes 
(Table 2, Fig. 3 for type 1 diabetes and Fig. 4 for type 2 
diabetes).
This phenomenon was seen across all ages in men and 
women with type 1 diabetes and progressively decreased 
with advancing age. In type 2 diabetes, this phenomenon 
was seen after 50 years, increased until 60–65 years and 
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then progressively decreased with advancing age (Fig.  3 
and Fig. 4).
With propensity score matching, 1,107,874 female 
patients were adequately matched in a 1:1 fashion with 
male patients (mean age 62.4 ± 16.5, Additional file  1: 
Table  S4, Fig. S1). Cumulative incidences for first-time 
AF in matched male and female patients during follow-
up are presented in Additional file 1: Fig. S2, with lower 
incidence of AF in female patients. Additional file 1: Fig. 
S3 shows cumulative incidences for first-time AF during 
follow-up in matched male and female patients for type 
1 diabetes and type 2 diabetes vs no diabetes. The overall 
Table 1 Baseline characteristics of  patients seen in  French hospitals in  2013 with  at  least 5  years of  follow-up (mean 
follow-up 4.8 ± 1.7 years, median 5.5, IQR 5.1–5.8 years) according to sex and diabetes
Values are n (%) or mean ± SD
CABG coronary artery bypass graft, COPD chronic obstructive pulmonary disease, PCI percutaneous coronary intervention, SD standard deviation
Women (n = 1,596,521) Men (n = 1,324,886) p Total (n = 2,921,407)
Age, years 57.4 ± 20.2 62.4 ± 15.7  < 0.0001 59.7 ± 18.5
Hypertension 394,909 (24.7) 414,073 (31.3)  < 0.0001 808,982 (27.7)
Type 1 diabetes mellitus 21,440 (1.3) 23,949 (1.8)  < 0.0001 45,389 (1.6)
Type 2 diabetes mellitus 158,536 (9.9) 186,963 (14.1)  < 0.0001 345,499 (11.8)
Heart failure 78,953 (4.9) 118,967 (9.0)  < 0.0001 197,920 (6.8)
History of pulmonary edema 6134 (0.4) 8133 (0.6)  < 0.0001 14,267 (0.5)
Valve disease 31,293 (2.0) 33,494 (2.5)  < 0.0001 64,787 (2.2)
Aortic stenosis 12,777 (0.8) 15,286 (1.2)  < 0.0001 28,063 (1.0)
Aortic regurgitation 5961 (0.4) 6842 (0.5)  < 0.0001 12,803 (0.4)
Mitral regurgitation 11,861 (0.7) 11,598 (0.9)  < 0.0001 23,459 (0.8)
Previous endocarditis 719 (0.0) 1715 (0.1)  < 0.0001 2434 (0.1)
Dilated cardiomyopathy 15,679 (1.0) 25,281 (1.9)  < 0.0001 40,960 (1.4)
Coronary artery disease 80,028 (5.0) 180,628 (13.6)  < 0.0001 260,656 (8.9)
Previous myocardial infarction 13,781 (0.9) 29,458 (2.2)  < 0.0001 43,239 (1.5)
Previous PCI 17,071 (1.1) 54,082 (4.1)  < 0.0001 71,153 (2.4)
Previous CABG 1332 (0.1) 5455 (0.4)  < 0.0001 6787 (0.2)
Vascular disease 66,211 (4.1) 152,831 (11.5)  < 0.0001 219,042 (7.5)
Sinus node disease 4839 (0.3) 6677 (0.5)  < 0.0001 11,516 (0.4)
Previous pacemaker or ICD 18,282 (1.1) 35,437 (2.7)  < 0.0001 53,719 (1.8)
Ischemic stroke 18,064 (1.1) 24,153 (1.8)  < 0.0001 42,217 (1.4)
Intracranial bleeding 11,518 (0.7) 15,023 (1.1)  < 0.0001 26,541 (0.9)
Smoker 77,467 (4.9) 130,941 (9.9)  < 0.0001 208,408 (7.1)
Dyslipidemia 154,413 (9.7) 204,085 (15.4)  < 0.0001 358,498 (12.3)
Obesity 173,764 (10.9) 124,824 (9.4)  < 0.0001 298,588 (10.2)
Alcohol related diagnoses 43,979 (2.8) 123,782 (9.3)  < 0.0001 167,761 (5.7)
Chronic kidney disease 36,061 (2.3) 47,271 (3.6)  < 0.0001 83,332 (2.9)
Diabetic retinopathy 13,416 (0.8) 16,111 (1.2)  < 0.0001 29,527 (7.6)
Lung disease 113,325 (7.1) 146,430 (11.1)  < 0.0001 259,755 (8.9)
Sleep apnea syndrome 40,091 (2.5) 67,314 (5.1)  < 0.0001 107,405 (3.7)
COPD 46,967 (2.9) 92,916 (7.0)  < 0.0001 139,883 (4.8)
Liver disease 37,124 (2.3) 61,683 (4.7)  < 0.0001 98,807 (3.4)
Gastroesophageal reflux 55,429 (3.5) 43,668 (3.3)  < 0.0001 99,097 (3.4)
Thyroid diseases 111,988 (7.0) 27,696 (2.1)  < 0.0001 139,684 (4.8)
Inflammatory disease 84,357 (5.3) 66,951 (5.1)  < 0.0001 151,308 (5.2)
Anaemia 115,265 (7.2) 96,982 (7.3) 0.001 212,247 (7.3)
Previous cancer 197,346 (12.4) 245,236 (18.5)  < 0.0001 442,582 (15.1)
Poor nutrition 50,124 (3.1) 46,689 (3.5)  < 0.0001 96,813 (3.3)
Cognitive impairment 48,277 (3.0) 35,666 (2.7)  < 0.0001 83,943 (2.9)
Illicit drug use 4036 (0.3) 9041 (0.7)  < 0.0001 13,077 (0.4)
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Fig. 1 Flow chart of studied patients
Fig. 2 Incidence rates of atrial fibrillation according to age by decade, stratified by diabetes status
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results were consistent with those from the unmatched 
adjusted analysis. The higher risk of AF associated with 
type 1 diabetes was more marked in women than in men: 
HR 1.56, 95% CI 1.49–1.63 in women vs 1.12, 95% CI 
1.08–1.16 in men, WMR (HR women compared to HR 
in matched men) 1.39, 95% CI 1.32–1.48. This difference 
was less marked with type 2 diabetes: HR 1.82, 95% CI 
1.80–1.85 in women vs 1.67, 95% CI 1.65–1.69 in men, 
WMR 1.10, 95% CI 1.08–1.12.
Discussion
In our large nationwide contemporary analysis our prin-
cipal finding was that incidence of AF was significantly 
higher both in type 1 and type 2 diabetic patients than 
in patients with no diabetes, and both for men and for 
women. Second, there was a significantly higher relative 
risk of AF in diabetic versus nondiabetic women by com-
parison to the same risk evaluated in men, both for type 
1 and type 2 diabetes. Third, we found that the sex differ-
ences across ages for the risk of AF were different for type 
1 and type 2 diabetes.
In type 2 diabetes, AF is not uncommon, and for exam-
ple, 7.6% of patients had AF at baseline in the ADVANCE 
study [18]. The incidence of AF has been reported to 
be around two-fold higher in patients with diabetes 
compared with people without diabetes [19], and AF 
incidence may be even higher in patients with micro-
vascular complications (retinopathy, renal disease) [20]. 
In a meta-analysis which included 7 prospective studies 
and 4 case–control studies on 1.7 million subjects, dia-
betes was associated with about 40% higher risk of AF; 
however, after adjustment, the effect was more limited 
with an increased risk of only 24% [3]. The risk of type 2 
diabetes on incident AF was 28% greater vs controls in a 
recent Swedish cohort study [21]. The results in our large 
adjusted analysis in almost 3 million subjects indicates 
that the adjusted excess risk was lower, around 15% (10% 
for men and 17% for women with type 2 diabetes). This 
was consistent with a previous analysis in 34,720 female 
health professionals which was inadequately powered to 
reach statistical significance (HR 1.14, 95% CI 0.93–1.40) 
[22]. Similarly, prevalence of elevated blood glucose level 
among residents in Guangzhou, China was associated 
with an increase in prevalence of AF, which was higher 
in women [23]. In a recent Spanish nationwide analysis, 
the incidence of hospitalization for AF was also higher 
Table 2 Unadjusted and  multivariable-adjusted HRs for  incidence of  AF comparing people with  and  without diabetes 
by sex, and hazard ratio for women relative to men
Adjusted for age at inclusion and baseline characteristics (among smoking, obesity, hypertension, hypercholesterolemia, alcohol abuse, previous stroke, and non-
cardiovascular comorbidities). Women to men ratio > 1 indicates an excess risk for incident AF in women with prevalent type 1 or type 2 diabetes mellitus compared 
with men with prevalent similar type of diabetes mellitus
HR hazard ratio, WMR women-to-men ratios






Hazard ratio (95% CI) Women-to-men ratio (95% 
CI)
Diabetes vs  no diabetes (HR in women/HR in men)
Unadjusted Adjusted Unadjusted Adjusted
Women
 No diabetes 1,416,545 6,855,046.80 114 855 1.68 (1.67–
1.69)
 Type 1 
diabetes






 Type 2 
diabetes





















 No diabetes 1,113 974 4 971 106.10 145 269 2.92 (2.91–
2.94)
 Type 1 
diabetes






 Type 2 
diabetes
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Fig. 3 Incidence rates of first-time AF according to age, stratified by diabetes status and sex (top panel), hazard ratios stratified by sex (middle 
panel), and women-to-men ratios (lower panel) of first-time AF according to age by decade for type 1 diabetes vs no diabetes. Higher hazard ratio 
in women if women-to-men ratios > 1. HR, hazard ratios; WMR, women-to-men ratios
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Fig. 4 Incidence rates of first-time AF according to age, stratified by diabetes status and sex (top panel), hazard ratios stratified by sex (middle 
panel), and women-to-men ratios (lower panel) of first-time AF according to age by decade for type 2 diabetes vs no diabetes. Higher hazard ratio 
in women if women-to-men ratios > 1. HR, hazard ratios; WMR, women-to-men ratios
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in women with type 2 diabetes than in diabetic men [24]. 
Our original age-stratified analysis indicated that the 
excess risk in women was mainly observed in middle-
aged patients. WMR increased after the age of 40 reach-
ing a plateau at 1.3 at the age of 55 continuing until the 
age of 70 before sliding down to 1.1 at the age of 85.
Studies on type I diabetes in relation to AF risk are 
rarer, but recent large analyses eventually confirmed that 
type I diabetes was also independently associated with a 
higher incidence of AF [11, 25]. This point was previously 
a matter of debate, and (for example) was not reported 
in a recent analysis of 71,483 Swedish adults, which was 
underpowered considering the much lower prevalence of 
type 1 diabetes compared to type 2 diabetes [26]. By con-
trast, our analysis had sufficient statistical power to dem-
onstrate that (1) type 1 diabetes was also associated with 
a significantly higher incidence of AF than in non-diabet-
ics patients, indicating that insulin resistance would not 
be the only promoter of AF in patients with diabetes (2) 
this association was seen both in men and in women, (3) 
the adjusted hazard ratios for the risk of AF were actu-
ally even higher than for type 2 diabetes, particularly for 
women and (4) the higher relative risk of AF in women 
was seen across all ages, the women-to-men ratio being 
around 1.8 at age 45 and progressively decreasing with 
increasing age, which was somewhat different than what 
was seen for type 2. Recent pre-clinical studies suggested 
that loss of insulin signalling may contribute to atrial 
electrical remodelling and atrial fibrillation in murine 
models of type 1 diabetes [27].
Although several putative explanations may be sug-
gested, there are currently no definite mechanisms for 
these sex differences across ages for type 1 and type 2 
diabetes. These difference in risk may result from the 
complex interplay of hormonal homeostasis, other car-
diovascular risk factors and psychosocial factors [28]. 
Diabetes may abrogate the protective effect of the female 
sex against cardiovascular complications across all age 
[29] and AF may be the consequence of these cardiovas-
cular complications. Type 2 diabetes mellitus has been 
associated with impairment of nitric oxide dependent 
endothelial function in premenopausal diabetic women 
contributing to the incidence of some of these macrovas-
cular complications [30]. Women with well-controlled 
diabetes mellitus may experience more coronary micro-
vascular dysfunction leading to more severe diastolic 
function than diabetic men [31] which may also be a pro-
moter for AF. High variability in bodyweight may also be 
associated with AF development in patients with type 2 
diabetes, independently of traditional cardiovascular risk 
factors and baseline BMI, and is more likely to be seen 
in women [32]. Interestingly, the use of sodium-glucose 
cotransporter 2 (SGLT2) inhibitor drugs may provide 
protection against several cardiovascular adverse events, 
both for men and women with type 2 diabetes [33]. 
Among the SGLT2 inhibitor drugs, dapaglifozin has been 
shown to decrease the incidence of AF [34].
Nonetheless, these mechanisms may not fully explain 
the excess risk compared to men and other factors have 
been suggested such as less aggressive global control of 
risk factors [12, 35]. Women with diabetes may be less 
likely to have HbA1c < 7%, to receive lipid-lowering medi-
cation and, when treated, to achieve recommended lipid 
and blood pressure targets [36], whilst prevention of AF 
relies on the identification and management of risk fac-
tors and comorbidities predisposing to AF, before the 
development of atrial remodelling and fibrosis [37]. 
In our study, medication use was retrieved from a 1/97 
representative sample of patients, and diabetic women 
were less likely to receive angiotensin-converting enzyme 
inhibitors, aspirin, P2Y12 inhibitors or statin than dia-
betic men. We acknowledge that this observation is only 
exploratory and therefore hypothesis generating. Our 
observations suggest that specific studies investigating 
more aggressive preventive measures in diabetic women 
are warranted. Of note, a higher rate of complications 
has been reported in women with catheter ablation of 
AF, which may be partially attributable to older age and 
a higher prevalence of comorbidities (including diabetes) 
at the time of ablation [38].
Limitations
We acknowledge several limitations to our work. A main 
limitation is inherent to the retrospective, observational 
nature of the study and its potential biases. Further, the 
study was based on administrative data, with limitations 
inherent to such methodology. The PMSI database con-
tains diagnoses coded using ICD-10, which are obtained 
at hospital discharge and are the physician’s responsibil-
ity. Data were not systematically externally checked and 
this could have caused information bias. However, the 
large scale of the database is likely to partly compensate 
some of these biases and, as coding of complications is 
linked to reimbursement and is regularly controlled, it is 
expected to be of good quality. Type 2 diabetes is widely 
treated in the primary sector by general practitioners and 
some of these patients may have not been included in the 
analysis. It is possible that patients with type 2 diabetes 
in this study could represent the more ill or with more 
comorbidity requiring in hospital care.
Events included were only in-hospital and we were not 
able to analyse data for out-of-hospital visits with AF. 
Our large population of hospitalized patients likely rep-
resents a heterogeneous group of patients admitted with 
various kinds of illnesses of different severities, which 
may have affected prognosis. Thus, the results might not 
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be fully representative of more general population and 
further investigations would be valuable in the general 
‘non-hospitalised’ population. Patients with diabetes had 
more prevalent comorbidities compared to those without 
diabetes and it is possible that those with diabetes were 
more often seen by healthcare personal, hence increasing 
the likelihood of silent AF being found randomly. How-
ever, there is no clear reason that this possible bias may 
more markedly affect women than men after adjustment 
on cardiovascular risk factors and non-cardiovascular 
comorbidities. Another limitation is the lack of com-
plete information in terms of therapies recommended 
for diabetes or cardiovascular conditions beyond the 
representative sample from our analysis. Further, the 
non-randomized design of the analysis leaves a risk of 
residual confounding factors. Our analysis was restricted 
to the variables present in the database, which meant 
that characteristics such as information on some of the 
lifestyle factors (physical activity level or diet), metabolic 
control (glycemic control, lipids, body mass index and 
blood pressure) or imaging (echocardiography including 
measures of systolic function or left atrial size) were not 
available for analysis. Finally, the majority of the French 
population is white European and our results may not be 
generalizable to non-white European people.
Conclusions
In a contemporary nationwide study, we found that 
diabetes was associated with a 10% to 30% higher inci-
dence of AF after adjustment on other baseline risk fac-
tors, which was highest in women with type 1 diabetes. 
Although diabetic men have higher absolute incidence 
of AF, the relative incidences of AF were higher in dia-
betic women than in diabetic men, both for type 1 and 
type 2 diabetes. This phenomenon was seen across all 
ages in men and women with type 1 diabetes and pro-
gressively decreased with advancing age. By contrast, 
the excess risk in women compared to men was mainly 
observed in middle-aged patients in type 2 diabetes.
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